key: cord-0744530-l07siasy
authors: Taramasso, Lucia; Sepulcri, Chiara; Mikulska, Malgorzata; Magnasco, Laura; Lai, Alessia; Bruzzone, Bianca; Dentone, Chiara; Bassetti, Matteo
title: Duration of isolation and precautions in immunocompromised patients with COVID-19
date: 2021-02-22
journal: J Hosp Infect
DOI: 10.1016/j.jhin.2021.02.014
sha: 572972b69a2592d2ab792cc091658e182a72db3b
doc_id: 744530
cord_uid: l07siasy

nan

Mail address: chiara.dentone@hsanmartino.it Current international guidelines [1] recommend, for most persons with COVID-19 illness, discontinuation of isolation and precautions after 10 days from the onset of symptoms and after at least 24 hours without fever. A longer period of isolation, up to 20 days after symptom onset, is recommended for patients with severe illness. The lack of infectivity in people with duration of symptoms > 20 days has important implications on public health policy and in hospital infection control. However, these indications might not apply to immunocompromised patients, who might require longer time to obtain viral clearance [2] . For this reason, in such population, the correct timing of isolation is still to be ascertained. Therefore, we wanted to report our experience and the results of literature review focused on prolonged shedding of a viable virus in immunocompromised patients.

We report three cases of immunocompromised patients cared for in our Infectious Disease Unit in Northern Italy-Policlinic IRCCS San Martino University Hospital, Genoa-two with hematologic malignancies and one with rituximab-treated neuromyelitis optica (Table 1) The literature review identified other ten cases of immunocompromised patients in whom viable virus was cultured more than 10 days after the onset of infection, and, in most cases, also after more than 20 days (median 46.5 days, range: 17-119, Table1). Of note, not only severely ill patients had a prolonged shedding of viable virus, but also those with mild or asymptomatic infection.

These results advocate for customized public health policies and hospital infection control differentiation, not only based on the severity of COVID-19 illness, but also considering the baseline comorbid conditions and immune competence of the patients. A possible approach could be a test-based (PCR or antigen) strategy, as proposed for some cases of severely immunocompromised patients by the Center for Disease Control and Prevention [1] . However, it should be noted that intermittent negativity of molecular tests has also been reported for immunosuppressed patients [4, 5] and that, as a consequence, also the test-based approach might have gaps. Moreover, a shared definition of when considering persons " severely immunocompromised" is not provided by CDC indications [1] , while a prolonged shedding of viable SARS-CoV-2 virus has also been reported outside the settings of hematological malignancies or solid organ transplantation [4, 5] . Finally, some patients with a positive PCR result might not shed a viable virus, thus prolonging isolation might not be necessary.

In conclusion, special attention should be given to isolation precautions in immunocompromised people with SARS-CoV-2 infection, especially in hospital settings, even if only mild symptoms are present. Longer time should be considered before discontinuing precautions than in the immunocompetent, and viral culture might be useful to determine potential contagiousness of people with prolonged RT-PCR positivity in nasopharyngeal swabs. 

Duration of Isolation and Precautions for Adults with COVID-19

Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

SARS-CoV-2 positive virus culture 7 weeks after onset of COVID-19 in an immunocompromised patient suffering from X chromosome-linked agammaglobulinemia

Prolonged Severe Acute Respiratory Syndrome

Coronavirus 2 Replication in an Immunocompromised Patient

Shedding of Viable SARS-CoV-2 after

Immunosuppressive Therapy for Cancer

Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient

Shedding from an Asymptomatic Immunocompromised Individual with Cancer

Prolonged SARS-CoV-2 shedding and mild course of COVID-19 in a patient after recent heart transplantation

E: envelope gene; RdRp: polymerase gene; N: nucleocapsid protein gene; S: Spike protein gene; Orf1ab: open reading frame 1a and 1b